Performance of Ti/Pt and Nb/BDD anodes for dechlorination of nitric acid and regeneration of silver(II) in a tubular reactor for the treatment of solid wastes in nuclear industry

One of the problems frequently encountered in the processing of nuclear fuels is the recovery of plutonium contained in various solid wastes. The difficulty is to make soluble the plutonium present as the refractory oxide PuO2. The dissolution of this oxide in nitric acid solutions is easily performed by means of silver(II) a strong oxidizing agent which is usually electrochemically generated on a platinum anode. However, certain solid residues that must be treated to separate actinides contain important quantities of chloride ions that require after dissolution in nitric acid a preliminary electrochemical step to be removed before introducing Ag(I) for Ag(II) electrogeneration. Research is conducted to find electrocatalytic materials being able to replace massive platinum in view to limit capital costs. In the present work a set-up including a two-compartment tubular reactor with recirculation of electrolytes was tested with anodes made of boron doped diamond coated niobium (Nb/BDD) and platinum coated titanium (Ti/Pt) grids for the removal of chlorides (up to 0.1 M) and for silver(II) regeneration. The study showed that these two anodes are effective for the removal of chlorides contained in 6 M HNO3 solution as gaseous chlorine, without producing the unwanted oxyanions of chlorine. Furthermore, the regeneration rate of silver(II) on Nb/BDD anode is approximately equal to that obtained on Ti/Pt anode for the same hydrodynamic conditions in the tubular reactor. Accordingly, dechlorination as well as silver(II) regeneration can be performed in the same reactor equipped either with a Nb/BDD or a Ti/Pt anode. Besides, the service life of Nb/BDD anodes estimated by accelerated life tests conducted in 6 M HNO3 can be considered as very satisfactory compared to that observed with Ti/Pt anodes

Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer

Lung and bladder cancers are mostly incurable because of the early development of drug resistance and metastatic dissemination. Hence, improved therapies that tackle these two processes are urgently needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and metastasis in lung and bladder cancer cells. Silencing this kinase, through either RNA interference or CRISPR, sensitized tumor cells to chemotherapy and hindered metastasis in vitro and in vivo in a tail vein injection model. Drug screening revealed several floxacin antibiotics as potent RSK4 activation inhibitors, and trovafloxacin reproduced all effects of RSK4 silencing in vitro and in/ex vivo using lung cancer xenograft and genetically engineered mouse models and bladder tumor explants. Through x-ray structure determination and Markov transient and Deuterium exchange analyses, we identified the allosteric binding site and revealed how this compound blocks RSK4 kinase activation through binding to an allosteric site and mimicking a kinase autoinhibitory mechanism involving the RSK4’s hydrophobic motif. Last, we show that patients undergoing chemotherapy and adhering to prophylactic levofloxacin in the large placebo-controlled randomized phase 3 SIGNIFICANT trial had significantly increased (P = 0.048) long-term overall survival times. Hence, we suggest that RSK4 inhibition may represent an effective therapeutic strategy for treating lung and bladder cancer